MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2017 International Congress

    Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared With Placebo in Adult Patients With Cervical Dystonia

    M. Lew, D. Snyder (Los Angeles, CA, USA)

    Objective: To determine the efficacy and safety of a 500 U/2 mL dilution of aboBoNT-A as compared to placebo in patients with cervical dystonia (CD).…
  • 2017 International Congress

    A Phase 2, Open-Label, Dose-Escalating Study to Evaluate the Safety and Preliminary Efficacy of Daxibotulinumtoxina for Injection (RT002) in Isolated Cervical Dystonia

    C. Comella, J. Jankovic, D. Truong, A. Brashear, A. Patel, M. Evatt, C. Chung, R. Rubio (Chicago, IL, USA)

    Objective: To report preliminary 24-week outcomes of an open-label trial of daxibotulinumtoxinA for injection (RT002) for the treatment of isolated cervical dystonia (CD). (ClinicalTrials.gov ID: NCT02706795) Background:…
  • 2017 International Congress

    Regional differences may influence the drivers of change in Toronto Western Spasmodic Rating Scale (TWSTRS) scores following botulinum toxin treatment: Analysis of an international observational study

    V. Misra, D. Charles, T.M. Chung, C. Colosimo, S. Om, P. Maisonobe (London, United Kingdom)

    Objective: Investigate the drivers for change in Toronto Western Spasmodic Rating Scale (TWSTRS) scores in subjects with cervical dystonia (CD) following a single injection of…
  • 2017 International Congress

    Cost-utility analysis of flexible interval incobotulinumtoxinA versus onabotulinumtoxinA in the management of blepharospasm and cervical dystonia in Ontario, Canada.

    M.-E. Gendron, M.-E. Gendron, R. Kazerooni (Burlington, ON, Canada)

    Objective: To carry out a cost-utility analysis for IncoBTX administered with flexible treatment intervals compared to OnaBTX in the management of BL and CD from…
  • 2017 International Congress

    Impact of injection interval on patient satisfaction in the routine treatment of cervical dystonia with abobotulinumtoxinA

    R. Trosch, V. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

    Objective: Evaluate the impact of injection interval on patient satisfaction with abobotulinumtoxinA (AboBoNT-A; Dysport®) over 1 injection cycle in patients with cervical dystonia (CD). Background:…
  • 2017 International Congress

    Injection guidance use in the management of cervical dystonia with botulinum toxin

    D. Charles, T.M. Chung, C. Colosimo, V. Misra, P. Maisonobe, S. Om (Nashville, TN, USA)

    Objective: Investigate the use of injection guidance techniques and their impact on patient outcomes in the routine management of cervical dystonia (CD) with botulinum neurotoxin…
  • 2016 International Congress

    Does GPi-DBS help non motor symptoms in cervical dystonia patients? A retrospective study of 17 patients

    L. Lowry, B. Hammersley, M. Bonello, P. Byrne, N.A. Fletcher, J.O. Farah, P.R. Eldridge, S.H. Alusi (Liverpool, United Kingdom)

    Objective: To study the efficacy of GPi DBS surgery in improving dystonia related severity, disability and pain as well as quality of life in medically…
  • 2016 International Congress

    Structural and connectivity changes after botulinum neurotoxin therapy in blepharospasmus and hemifacial spasm

    C.V. Chirumamilla, G. Deuschl, K.E. Zeuner, M. Muthuraman, S. Groppa (Mainz, Germany)

    Objective: The two primary objectives of this study were to investigate the structural grey matter changes and connectivity differences between patients with BEB and HFS…
  • 2016 International Congress

    Quality of life and epidemiological profile of patients undergoing botulinum toxin treatment

    G. Amorelli, L.F. Vasconcellos, M. Spitz, L.F. Fraga (Rio de Janeiro, Brazil)

    Objective: To trace a clinical and epidemiological profile of patients treated with botulinum toxin, evaluating the impact on quality of life. Background: The Botulinum Toxin…
  • 2016 International Congress

    Assessment of need for treatment with botulinum toxin type A in cervical dystonia patients

    C.L. Vaughan, G.T. Stebbins, C.L. Comella (Charleston, SC, USA)

    Objective: To prospectively assess the interval in weeks between injection of botulinum toxin A (BoNTA) and patient-perceived need for the next injection for treatment of…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29509 (not found)
  • #22661 (not found)
  • #25778 (not found)
  • #25945 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley